Dry AMD Symposium 2

Related

• 

  Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics

  David R Lally, MD

  Annual Meeting Talks

  2021

• 

  Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials

  Carl D. Regillo, MD

  Annual Meeting Talks

  2019

• 

  Sustained Diabetic Retinopathy Severity Improvement With Intravitreal Aflibercept in DME: Post Hoc Analysis of VISTA and VIVID

  Rishi P. Singh, MD

  Annual Meeting Talks

  2019